Pacer Advisors Inc. Buys 6,237 Shares of Zoetis Inc. (NYSE:ZTS)

Pacer Advisors Inc. boosted its position in Zoetis Inc. (NYSE:ZTS) by 15.4% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 46,611 shares of the company’s stock after purchasing an additional 6,237 shares during the quarter. Pacer Advisors Inc.’s holdings in Zoetis were worth $9,107,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. German American Bancorp Inc. increased its position in shares of Zoetis by 10.9% during the third quarter. German American Bancorp Inc. now owns 21,046 shares of the company’s stock worth $4,112,000 after purchasing an additional 2,065 shares in the last quarter. Landscape Capital Management L.L.C. acquired a new position in Zoetis during the 3rd quarter valued at about $458,000. King Luther Capital Management Corp raised its stake in Zoetis by 1.5% in the third quarter. King Luther Capital Management Corp now owns 1,815,949 shares of the company’s stock valued at $354,800,000 after buying an additional 26,918 shares during the last quarter. Altman Advisors Inc. acquired a new stake in Zoetis in the third quarter worth about $1,729,000. Finally, Darwin Wealth Management LLC purchased a new stake in shares of Zoetis during the third quarter worth about $31,000. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Trading Up 0.1 %

ZTS stock opened at $176.96 on Friday. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $201.92. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26. The firm has a market cap of $79.84 billion, a P/E ratio of 33.26, a PEG ratio of 2.71 and a beta of 0.90. The company’s 50-day simple moving average is $185.62 and its 200-day simple moving average is $180.61.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Monday, November 4th. The company reported $1.58 EPS for the quarter, beating the consensus estimate of $1.46 by $0.12. The company had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.29 billion. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. Zoetis’s quarterly revenue was up 11.6% compared to the same quarter last year. During the same period last year, the company earned $1.36 earnings per share. As a group, equities analysts forecast that Zoetis Inc. will post 5.9 EPS for the current fiscal year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 3rd. Shareholders of record on Thursday, October 31st will be issued a dividend of $0.432 per share. This represents a $1.73 annualized dividend and a yield of 0.98%. The ex-dividend date of this dividend is Thursday, October 31st. Zoetis’s payout ratio is 32.52%.

Analyst Upgrades and Downgrades

Several brokerages recently commented on ZTS. Piper Sandler increased their price objective on shares of Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research report on Wednesday, August 14th. BTIG Research lifted their price objective on shares of Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Stifel Nicolaus boosted their price objective on shares of Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a report on Wednesday, September 18th. JPMorgan Chase & Co. raised their target price on Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research note on Friday, October 11th. Finally, Argus raised Zoetis to a “strong-buy” rating in a report on Friday, August 9th. Ten investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $221.44.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.